- 4mg/2ml and 8mg/4ml ampoules (IV, IM)

- 4 and 8mg tablets (PO, oral disintegrating tablets)

Executive Summary

(April 24, 2023)

Ondansetron is a selective serotonin receptor antagonist (5HT-3) with proven antiemetic properties, used in both children and adults to treat nausea and vomiting caused by a variety of conditions; such as chemotherapy, gastroenteritis, migraine, traumatic brain injury, etc. (3, 5, 17).

Adult dose for nausea and/or vomiting
4 to 8mg PO or IV.

Adult dose

Adult dose for nausea and/or vomiting
4 to 8mg PO or IV.

Pediatric dose

Pediatric dose for nausea and/or vomiting (13)
0.15mg/kg PO, IV


Acute gastroenteritis and ondansetron

Pathophysiology of antiemetic drugs

Although nausea and vomiting are common, there are few studies comparing antiemetic drugs for specific disorders. Most studies have focused on patients undergoing chemotherapy. As a result, drug selection in many situations is based on empirical evidence, preferred routes of administration, and safety considerations.

Mechanism of action and pharmacology

Renal, hepatic and age adjustements


Pregnancy and Lactation

Pregnancy risk classification

Lactation (23)



® 2023 EMDrugs. All rights reserved.



This website provides general information and discussion about medications, health, and related subjects. The words and other con­tent pro­vided in this website, and in any linked mate­ri­als, are not intended and should not be con­strued as med­ical advice. If the reader or any other per­son has a med­ical con­cern, he or she should con­sult with an appropriately-licensed physi­cian or other legally accredited health care worker in the country that resides or is visiting. 


Please do not delay your medical concerns and potential health emergencies by searching information in this website, instead look out for medical opinion in the services that exist with that specific purpose and work under the respective local health-care regulations. 


The views expressed on this blog and web­site have no rela­tion to those of any academic, hospital, practice or other insti­tu­tion with which the authors are  affiliated. 


For other instances, the authors of this website do not have any conflict of interest with any institution or pharmaceutical company in particular, and do not receive any compensation about any licenced drug mentioned in the website. In the same matter, the website is not intended to recommend any specific patented medication.

EMDrugs Team